简体中文 English

Pipeline

Partner


Phase III

Preclinical

Phase II

Drug Candidates

Region of right


Phase I

 
 


CN201

 
Rest of World

Rest of World


CN401 (Tenalisib)


Greater China


 

CN1


 

CN202


 

CN808002


 

CN808005